I farmaci antitrombotici in gravidanza.

Translated title of the contribution: Antithrombotic agents in pregnancy

G. F. Gensini, M. Comeglio, R. Abbate

Research output: Contribution to journalArticlepeer-review


The need for antithrombotic therapy during pregnancy is a challenging problem for the clinician. Pregnancy per se is associated with a prothrombotic state, and some conditions definitely require anticoagulant treatment. However, all three main antithrombotic agents (coumarins, heparin and aspirin) have potential serious adverse effects for the mother and fetus. The aim of this review was to discuss the modifications of the coagulation system during pregnancy, and try to properly state the indications and the best schedule of antithrombotic treatment during pregnancy. Presently heparin is considered the anticoagulant of choice for the treatment and prevention of venous thromboembolic disorders and in patients with congenital or acquired thrombophilic conditions. The use of oral anticoagulants is still preferred in women with prosthetic heart valves or atrial fibrillation, but they cannot be administered between the sixth and twelfth week and in the last month of gestation because of the teratogenic and hemorrhagic risks related to their use. Low-dose aspirin is useful for the prevention of pre-eclampsia, intrauterin growth retardation, and in association with heparin or prednisone, for the prevention of abortion in patients with antiphospholipid antibodies.

Translated title of the contributionAntithrombotic agents in pregnancy
Original languageItalian
Pages (from-to)357-365
Number of pages9
Issue number12 Suppl 1
Publication statusPublished - Dec 1994

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Antithrombotic agents in pregnancy'. Together they form a unique fingerprint.

Cite this